Results 231 to 240 of about 41,304 (260)
Some of the next articles are maybe not open access.

Direct oral anticoagulants today

Medicina Clínica (English Edition), 2021
Carlos, Escobar Cervantes   +1 more
openaire   +2 more sources

Direct Oral Anticoagulants in Cancer Patients

Seminars in Thrombosis and Hemostasis, 2019
AbstractCancer-associated thrombosis (CAT) is a common occurrence in the journey of a cancer patient and its management poses significant challenges. Low molecular weight heparin (LMWH) is the standard of care but the high cost and the inconvenience of daily injections have led to low persistence with therapy.
Deepa, Suryanarayan   +2 more
openaire   +2 more sources

Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants

The Lancet Haematology
Over the last decade, the advent of direct oral anticoagulants (DOACs) has rapidly changed the landscape of anticoagulation. In the early 2010s, DOACs became widely available for stroke prevention in atrial fibrillation and the treatment of venous thromboembolism.
Ageno W.   +4 more
openaire   +3 more sources

Direct Oral Anticoagulants

2015
Direct oral anticoagulants (DOACs) are rapidly changing the way we think about selecting, treating, and monitoring patients in need of anticoagulation. These agents may be used for either treatment or prophylaxis of systemic embolism and have been compared to vitamin K antagonist (e.g., warfarin) for many of the same indications.
openaire   +1 more source

Reversal of direct oral anticoagulants

British Journal of Hospital Medicine, 2018
Oliver, Cohen   +2 more
openaire   +2 more sources

Direct Oral Anticoagulant removal by a DOAC filter: Impact on lupus anticoagulant testing – Evaluation on spiked and patient samples

Research and Practice in Thrombosis and Haemostasis, 2022
Pieter M De Kesel, Katrien M J Devreese
exaly  

A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant

Research and Practice in Thrombosis and Haemostasis, 2021
James D Douketis   +2 more
exaly  

Reasons for Nonadherence to the Direct Oral Anticoagulant Apixaban

JACC: Advances, 2023
Derjung M Tarn, Janice B Schwartz
exaly  

Home - About - Disclaimer - Privacy